RNS Number : 6953K
Marlowe PLC
01 November 2024
 

1 November 2024

 

Marlowe plc

 

Total Voting Rights

 

In accordance with section 5.6.1 of the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rules (DTRs), Marlowe plc ("Marlowe" or the "Group") hereby notifies the market of the following:

The Group's issued capital as at 31 October 2024 consists of 85,689,727 ordinary shares of 50p each ("Ordinary Shares") with voting rights attached. Of these, no Ordinary Shares are held exclusive of voting rights in Treasury.

Therefore, the total number of voting rights in Marlowe as at 31 October 2024 is 85,689,727.

Shareholders may use the figure of 85,689,727 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in Marlowe under the DTRs.

 

For further information:


 

 

 

Marlowe plc


Lord Ashcroft, Interim Non-Executive Chair

Adam Councell, Chief Financial Officer

Benjamin Tucker, Head of Investor Relations & Strategy

www.marloweplc.com

Tel: +44 (0)20 3813 8498

IR@marloweplc.com

 

Cavendish Capital Markets Limited (Nominated Adviser & Joint Broker)

Ben Jeynes

George Lawson

Tel: +44 (0)20 7220 0500



Investec Bank (Joint Broker)


Henry Reast

Oliver Cardigan

Tel: +44 (0)20 7597 5970

FTI Consulting


Nick Hasell

Alex Le May

Tel: +44 (0)20 3727 1340

 

About Marlowe plc

Marlowe is a leader in business-critical services which ensures compliance with strict regulations and insurance requirements across Fire Safety & Security and Water & Air Hygiene. The Group has a national footprint and serves approximately 27,000 customers across office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBBBFTMTAMBFI